Polar Power, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Polar Power, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Dec 31, 2019 | $24.80M | May 14, 2020 |
| FY2019 | Dec 31, 2018 | $24.05M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $14.42M | Apr 1, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.30M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $13.97M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $15.29M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $16.06M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $16.90M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $9.03M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $24.80M | Mar 31, 2021 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($3.16M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $1.31M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $695.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $2.13M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $3.45M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($5.62M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $4.92M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $7.43M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $4.76M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $10.18M | Apr 2, 2018 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($9.13M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($4.68M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($6.55M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($5.58M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($1.41M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($10.87M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($4.05M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($848.3K) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($757.4K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $4.40M | Apr 2, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($8.42M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($4.38M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($5.99M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($5.53M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($3.10M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($12.96M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($3.98M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($1.10M) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($802.0K) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $7.40M | Apr 2, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $646.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $771.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $1.22M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $1.46M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $1.99M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.72M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.28M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $1.91M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.33M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $213.9K | Apr 2, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.06M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($536.0K) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($3.43M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($6.51M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($9.38M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($6.55M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($2.17M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | ($7.85M) | May 14, 2020 |
| FY2018 | Dec 31, 2017 | ($1.59M) | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $627.1K | Apr 2, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2024 | $19.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $194.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $25.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $71.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $19.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $338.0K | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $575.0K | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $342.1K | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $165.1K | Apr 2, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.44M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $17.55M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $25.26M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $24.19M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $27.18M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $17.80M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $23.56M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $25.24M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $24.52M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $26.63M | Apr 2, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $10.29M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $9.03M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $12.07M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $6.01M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $3.93M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $6.31M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $5.19M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.86M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $1.62M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $2.98M | Apr 2, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $144.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $8.51M | Apr 15, 2026 |
| FY2025 | Dec 31, 2023 | $13.19M | Apr 15, 2026 |
| FY2024 | Dec 31, 2022 | $18.18M | Mar 31, 2025 |
| FY2023 | Dec 31, 2021 | $23.25M | Apr 1, 2024 |
| FY2022 | Dec 31, 2020 | $11.49M | Mar 31, 2023 |
| FY2021 | Dec 31, 2019 | $18.38M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $22.38M | Mar 31, 2021 |
| FY2019 | Dec 31, 2017 | $22.90M | May 14, 2020 |
| FY2018 | Dec 31, 2016 | $23.65M | Apr 1, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($39.47M) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | ($30.34M) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | ($25.66M) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | ($19.11M) | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | ($13.53M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | ($12.11M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($1.24M) | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $2.80M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | $3.65M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | $4.41M | Apr 2, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $200.0K | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | $498.0K | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | $549.0K | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | $211.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | $5.10M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | $1.65M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $2.84M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | $5.64M | May 14, 2020 |
| FY2019 | Dec 31, 2017 | $14.20M | May 14, 2020 |
| FY2018 | Dec 31, 2016 | $16.24M | Apr 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $64.0K | Apr 1, 2024 |
| FY2022 | Dec 31, 2022 | $268.0K | Mar 31, 2023 |
| FY2021 | Dec 31, 2021 | $510.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | $777.0K | Mar 31, 2021 |
| FY2019 | Dec 31, 2019 | $1.11M | May 14, 2020 |
| FY2018 | Dec 31, 2018 | $1.21M | Apr 1, 2019 |
| FY2017 | Dec 31, 2017 | $237.1K | Apr 2, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Mar 31, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (3) | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | (3) | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Apr 1, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 2.68M | Apr 15, 2026 |
| FY2025 | Dec 31, 2024 | 2.51M | Apr 15, 2026 |
| FY2024 | Dec 31, 2023 | 2.51M | Mar 31, 2025 |
| FY2023 | Dec 31, 2022 | 12.95M | Apr 1, 2024 |
| FY2022 | Dec 31, 2021 | 12.79M | Mar 31, 2023 |
| FY2021 | Dec 31, 2020 | 11.75M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 10.13M | Mar 31, 2021 |
| FY2019 | Dec 31, 2018 | 10.14M | May 14, 2020 |
| FY2018 | Dec 31, 2017 | 10.14M | Apr 1, 2019 |
| FY2017 | Dec 31, 2016 | 10.14M | Apr 2, 2018 |